Navigation Links
Optimal dose of vitamin E maximizes benefits, minimizes risk
Date:10/30/2008

Corvallis, Oregon October 29, 2008 -- Vitamin E has been heralded for its ability to reduce the risk of blood clots, heart attack, and sudden death. Yet in some people, vitamin E causes bleeding. Scientists have known for more than 50 years that excess vitamin E promotes bleeding by interfering with vitamin K, which is essential in blood clotting. However, they haven't been able to pinpoint how the two vitamins interact. Nutrition researcher Maret Traber of Oregon State University reviews studies of possible explanations of the interaction in an article published recently in Nutrition Reviews.

One of the most compelling studies of the benefits of vitamin E is the Women's Health Study, in which 40,000 healthy women, 45 and older, took 600 IU vitamin E supplements or a placebo every other day for 10 years. Women taking the supplements had 24 percent fewer deaths from heart disease. Vitamin E's protective effect appeared even stronger in women 65 and older. Those taking the vitamin experienced a 26 percent reduction in cardiovascular events and a 49 percent reduction in cardiovascular deaths.

"That's a significant benefit," Traber said. Yet, she added, "In some people high doses of vitamin E increase the tendency to bleed. Women enrolled in the study had an increase in nose bleeds."

To lessen the bleeding risk, the U.S.-based Food and Nutrition Board in 2000 set the upper tolerable limit for daily vitamin E intake at 1500 I.U.

Research Traber reviewed suggests that a shared metabolic pathway in the liver causes vitamins E and K to interact. Vitamin K in the liver appears to diminish as vitamin E increases.

"Several different explanations could account for the interaction between the two vitamins," Traber said. "We need more research to understand the delicate balance between vitamins E and K."


'/>"/>

Contact: Amy Molnar
journalnews@bos.blackwellpublishing.net
201-748-8844
Wiley-Blackwell
Source:Eurekalert

Page: 1

Related biology news :

1. Genetics determine optimal drug dose of common anticoagulant
2. Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
3. Lack of vitamin D linked to Parkinsons disease
4. Vitamin D a key player in overall health of several body organs, says UC Riverside biochemist
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Dont forget the vitamin A when working with its carrier protein
7. Variant of vitamin D receptor gene linked to melanoma risk
8. Majority of osteoporosis patients not receiving calcium and vitamin D with treatment
9. Vitamin A pushes breast cancer to form blood vessel cells
10. Researchers identify cancer preventive properties in common vitamin supplement
11. Newborn vitamin A reduces infant mortality
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... (Edmonton) Thanks to important discoveries in basic and ... cancer has mobilized into a complex offensive spanning ... of Alberta chemistry lab could help find new ... developed a compound that targets a specific enzyme ... activity in cells from brain tumours. , Chemistry ...
(Date:8/22/2014)... Green tea polyphenols are strong antioxidants and ... protect spinal cord neurons against oxidative stress? ... Affiliated Hospital of Liaoning Medical University, China ... oxidative stress and inhibit neuronal apoptosis, indicating ... in spinal cord neurons under oxidative stress. ...
(Date:8/22/2014)... birds and the bees. But that old expression ... The fertilization process for flowering plants is particularly ... and female reproductive cells. New research from an ... and including Carnegie,s Wolf Frommer, David Ehrhardt, and ... process that guides flowering plant fertilization. It is ...
Breaking Biology News(10 mins):New enzyme targets for selective cancer therapies 2New enzyme targets for selective cancer therapies 3Calcium and reproduction go together 2
... cancer screening tests are proven to reduce colorectal cancer mortality, ... older receive the recommended tests, according to a report in ... Prevention , a journal of the American Association for Cancer ... conducted a National Health Interview Survey and found only 50 ...
... Using an engineered common cold virus, UCLA researchers delivered ... them, using Positron Emission Tomography (PET), to locate the ... the first place prostate cancer goes before invading other ... lymph nodes are very difficult to find using conventional ...
... probably one of the most commonly used diagnostics in ... the throat while the patient says, "Aaaah". But, research ... Journal of Medical Engineering and Informatics looks set ... The technique could circumvent the problem of the failing ...
Cached Biology News:Colorectal cancer screening rates still too low 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 2UCLA researchers locate and image prostate cancer as it spreads to lymph nodes 3Sounding out heart problems automatically 2
(Date:8/22/2014)... August 22, 2014 “Our nation's ... is a national disgrace. Furthermore, every governmental and ... the current, deplorable state of unorganized dysfunction shares ... mistakes," to merely serve as a device to ... of colossal failure(s) that have accumulated through the ...
(Date:8/21/2014)... 2014 Deep Research Report ... professional and in-depth research report on the ... Seaweed Fertilizer information, including Seaweed Fertilizer definition, ... well as industry overview. This research covers ... as well as global industry analysis covering ...
(Date:8/21/2014)... Mass. , Aug. 21, 2014  Decision ... Brazil and ... The uptake of several newly approved agents, the ... this indication and the launch of emerging biologics ... markets. In particular, the emerging IL-5 inhibitors will ...
(Date:8/21/2014)... August 21, 2014 Pursuit Solutions ... optimization technology and services for Life Sciences sales ... Pharma’s Use of New Commercial Sales Models” by ... Analytics. , The article examines some innovative models ... are being tested in the pharmaceutical market. Robinson ...
Breaking Biology Technology:5 Great Mistakes in Healthcare and How to Fix Them by Dr. Ira Williams 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 2Internationals Seaweed Fertilizer Industry 2014 Development Trend Analysis in New Research Study at DeepResearchReports.com 3Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... a carbon lattice with a honeycomb structure, has great ... electronic devices. But applications have been stymied because the ... not function effectively as a semiconductor to amplify or ... sheets into nanoscale ribbons can open up a larger ...
... , ... ... ... ...
... , ... ... ... ...
Cached Biology Technology:New graphene 'nanomesh' could change the future of electronics 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 2Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 3Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 4Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 5Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 6Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 7Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 8Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 9Shire Announces FDA Approval of VPRIV(TM) (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease 10Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 2Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 3Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 4Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 5Fate Therapeutics Named One of the 50 Most Innovative Companies in the World by MIT's Technology Review 6
Immunogen: Synthetic peptide (aa sequence is considered to be commercially sensitive) Storage: -20 C, Avoid Freeze/Thaw Cycles...
For use with SSP products or any application requiring agarose gel separation • Multiple formats available to meet various throughput needs • Includes replacement parts for each un...
recombination at attR1 and attR2 sites...
...
Biology Products: